UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/549,498	08/14/2006	Colin G. Caro	DEHN 2 00008	7739
²⁷⁸⁸⁵ FAY SHARPE	7590 02/08/200 LLP	EXAMINER		
	OR AVENUE, SEVEN	YARNALL, MEGAN LEIGH		
CLEVELAND,	CLEVELAND, OH 44114		ART UNIT	PAPER NUMBER
			3738	
			MAIL DATE	DELIVERY MODE
			02/08/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/549,498	CARO ET AL.			
Office Action Summary	Examiner	Art Unit			
	Megan Yarnall	3738			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w. - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	lely filed the mailing date of this communication. (35 U.S.C. § 133).			
Status					
Responsive to communication(s) filed on <u>31 December</u> 2a) This action is FINAL . 2b) This 3) Since this application is in condition for alloware closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro				
Disposition of Claims					
4) Claim(s) 1-13 is/are pending in the application. 4a) Of the above claim(s) is/are withdray 5) Claim(s) is/are allowed. 6) Claim(s) 1-13 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or Application Papers 9) The specification is objected to by the Examine 10) The drawing(s) filed on 14 September 2005 is/a Applicant may not request that any objection to the contraction.	vn from consideration. relection requirement. r. ure: a)⊠ accepted or b)⊡ object drawing(s) be held in abeyance. See	e 37 CFR 1.85(a).			
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 120605.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ite			

Page 2

DETAILED ACTION

Status of the Claims

Claims 14-27 are withdrawn from further consideration pursuant to 37 CFR
 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 12/31/2007.

Information Disclosure Statement

2. The information disclosure statement filed 12/06/2005 fails to comply with 37 CFR 1.98(a) (3) because it does not include a concise explanation of the relevance, as it is presently understood by the individual designated in 37 CFR 1.56(c) most knowledgeable about the content of the information, of each patent listed that is not in the English language. It has been placed in the application file, but the crossed out information has not been considered.

Specification

3. The following guidelines illustrate the preferred layout for the specification of a utility application. These guidelines are suggested for the applicant's use.

Arrangement of the Specification

As provided in 37 CFR 1.77(b), the specification of a utility application should include the following sections in order. Each of the lettered items should appear in upper case, without underlining or bold type, as a section heading. If no text follows the section heading, the phrase "Not Applicable" should follow the section heading:

- (a) TITLE OF THE INVENTION.
- (b) CROSS-REFERENCE TO RELATED APPLICATIONS.
- (c) STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT.
- (d) THE NAMES OF THE PARTIES TO A JOINT RESEARCH AGREEMENT.
- (e) INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ON A COMPACT DISC.
- (f) BACKGROUND OF THE INVENTION.

Application/Control Number:

10/549,498 Art Unit: 3738 Page 3

- (1) Field of the Invention.
- (2) Description of Related Art including information disclosed under 37 CFR 1.97 and 1.98.
- (g) BRIEF SUMMARY OF THE INVENTION.
- (h) BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S).
- (i) DETAILED DESCRIPTION OF THE INVENTION.
- (j) CLAIM OR CLAIMS (commencing on a separate sheet).
- (k) ABSTRACT OF THE DISCLOSURE (commencing on a separate sheet).
- (I) SEQUENCE LISTING (See MPEP § 2424 and 37 CFR 1.821-1.825. A "Sequence Listing" is required on paper if the application discloses a nucleotide or amino acid sequence as defined in 37 CFR 1.821(a) and if the required "Sequence Listing" is not submitted as an electronic document on compact disc).
- 4. Currently, the specification lacks section headings. Appropriate correction is required.

Double Patenting

5. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

6. Claims 1-13 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-13 of

10/549,498 Art Unit: 3738

copending Application No. 10/549211. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims only differ in terminology and intended use. The independent claim in both applications includes a tubular portion substantially free of ribs or grooves, wherein the center line of the lumen follows a helical path with a helix angle less than or equal to 65° and the amplitude of the helix is less than or equal to one half of the internal diameter of the tubing portion. The dependent claims are identical aside from the preamble which includes intended use of the product.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claim Rejections - 35 USC § 102

7. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.
- 8. Claims 1-11 are rejected under 35 U.S.C. 102(e) as being anticipated by Houston et al. 2002/0179166. Houston discloses a graft comprising flow tubing having a tubing portion 3 defining a flow lumen, the flow lumen of the tubing portion being substantially free of ribs or grooves (par.56), wherein the centre line of the flow lumen follows a substantially helical path with a helix angle less than or equal to 65° (par.10).

10/549,498 Art Unit: 3738

and wherein the amplitude of the helix is less than or equal to one half of the internal diameter of the tubing portion (figs.1-4B), and wherein the amplitude of the helical center line divided by the internal diameter of the tubing is at least 0.05 (figs. 4A,4B).

- 9. Re claim 4, wherein the wall has a helical portion extending longitudinally and circumferentially so as to resist reduction of the amplitude of the helical center line, see par.53.
- 10. Re claims 5 and 6, see fig.4A and par.52.
- 11. Re claim 8, see par.62, II.18-20.
- 12. Re claim 9, see par.20.
- 13. Re claims 10 and 11, see fig. 4A wherein 6 extends partially and substantially over tubing 3.

Claim Rejections - 35 USC § 103

- 14. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 15. Claim 12 is rejected under 35 U.S.C. 103(a) as being unpatentable over Houston et al. 2002/0179166. Houston discloses the invention substantially as claimed and as discussed above. Houston does not disclose a graft wherein the center line of the tubing portion follows a substantially helical path about an axis that is curved. However, providing a curved graft would have been obvious to one of ordinary skill in the art at the time of the invention because vessels that the graft replaces are typically curved, and in

order to bypass blockage in a vessel the graft would be required to be curved. Also, the graft of Houston is disclosed as being made from flexible materials and is therefore capable of being curved during use.

- 16. Claim 13 is rejected under 35 U.S.C. 103(a) as being unpatentable over Houston et al. 2002/0179166 in view of Healy et al. 5,670,161. Houston discloses the invention substantially as claimed. However, Houston does not disclose a graft comprising a pharmaceutical coating.
- 17. Healy discloses a stent graft, in the same field of endeavor, comprising a drug coating for the purpose of positively affecting healing at the site of implantation (col.10, II.10-13).
- 18. Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention to add a pharmaceutical coating to the graft disclosed by Houston in order to induce healing at the site of implantation, as taught by Healy, col.10, II.10-13. Further, it is well known in the art to coat a graft with pharmaceuticals to prevent thrombosis, etc.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Megan Yarnall whose telephone number is 571-270-3071. The examiner can normally be reached on Monday-Friday 7:00-4:30 EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Corrine McDermott can be reached on (571) 272-4754. The fax phone

10/549,498

Art Unit: 3738

number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/M. Y./ Examiner, Art Unit 3738 1/28/08

/Bruce E Snow/ Primary Examiner, Art Unit 3738